A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability
Latest Information Update: 22 Nov 2022
Price :
$35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Breast cancer; Ovarian cancer; Solid tumours
- Focus Therapeutic Use
- 16 Nov 2022 Planned End Date changed from 2 Oct 2022 to 2 Oct 2023.
- 16 Nov 2022 Planned primary completion date changed from 2 Oct 2022 to 2 Oct 2023.
- 04 Nov 2020 Planned End Date changed from 2 Oct 2020 to 2 Oct 2022.